News | November 14, 2025
LANXESS set to showcase cutting-edge infection control solutions
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Subscribe To Our Newsletter & Stay Updated
